Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01602419 · ClinicalTrials.gov registry record
Surveillance of Safety and Efficacy of Wilate in Patients With Von Willebrand Disease
A clinical trial, sponsored by Octapharma.
- Completed
- Registry status
- 120
- Enrollment target
NCT01602419: Completed study, sponsored by Octapharma.
NCT01602419 is a clinical trial that has completed, run by Octapharma. The registered enrollment target is 120 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01602419 has completed, sponsored by Octapharma.
- COMPLETED
- Registry status
- 120 participants
- Enrollment target
Study Summary
This is an observational study, hence there is no study hypothesis
Primary Outcome
Medical Dictionary for Regulatory Activities (MedDRA) primary system organ class preferred term. Incidence rate = number of patients reporting the event / number of patients \* 100
Interventions
- OTHER Patients using Wilate as standard of care
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2012-10 |
| Est. Completion | 2018-04 |
What the finished NCT01602419 record still lists
NCT01602419 is an observational study that tracks outcomes without assigning an intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Patients using Wilate as standard of care is the first listed.
NCT01602419 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01602419 about?
NCT01602419 is a clinical study titled "Surveillance of Safety and Efficacy of Wilate in Patients With Von Willebrand Disease". This is an observational study, hence there is no study hypothesis
What is the current status of trial NCT01602419?
This trial is currently completed. The enrollment target is 120 participants. The study started on 2012-10. Estimated completion is 2018-04.
What interventions are being tested in trial NCT01602419?
The interventions under investigation include: Patients using Wilate as standard of care (OTHER).
Who is sponsoring clinical trial NCT01602419?
This trial is sponsored by Octapharma, which has 43 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174108 · 120 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
- NCT01627301 · 120 participants · NA
Sympathetic Overactivity in Post-traumatic Stress Disorder
- NCT02025023 · 120 participants · Phase 3
Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study
- NCT02128906 · 120 participants · Phase 2
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia